Recent News

AffyImmune Therapeutics Announces Hiring of Matt Britz as Senior Vice President of Business Development

NATICK, Mass., June 21, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR-T cells against solid cancers, announced today the addition of Matt Britz to its management team as its Senior Vice President of Business Development. "Matt brings deep industry experience, a [...]

AffyImmune Therapeutics Announces First Patient Enrolled in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer

Natick, MA, October 29, 2020—AffyImmune Therapeutics today announced enrollment of the first patient in its Phase I clinical study evaluating AIC100, the company’s novel affinity-tuned CAR-T cell product, in patients with advanced, refractory thyroid cancer. The trial is designed to test safety, biological activity and real-time assessment of CAR T cell [...]

AffyImmune Therapeutics presents novel CAR T development programs at the annual meeting of the American Association of Cancer Research

June 29, 2020 – AffyImmune Therapeutics, Inc. disclosed novel advancements in their proprietary affinity-tuned CAR T-cell programs and technology in three presentations at the recent Annual Meeting of the American Association for Cancer Research (AACR). One presentation reported on a new CAR T design for localized and inducible cytokine release. The [...]